Clinical Trial Update: Pemetrexed and TAS-102 in Combination With Bevacizumab in Refractory Colorectal Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pemetrexed and TAS-102 in combination with bevacizumab for refractory colorectal cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms

Drugs mentioned

• Bevacizumab (bevacizumab)
• Pemetrexed (pemetrexed)
• TAS-102 (trifluridine/tipiracil)

Snippet

Sponsor: The First Affiliated Hospital with Nanjing Medical University | Conditions: Colorectal Neoplasms | Phase 2 | Status: UNKNOWN